Biovie Inc., of Beverly, Mass., said a second patient has been dosed with orphan drug candidate BIV-201 (continuous infusion terlipressin) in a phase IIa trial in patients with refractory ascites due to advanced liver cirrhosis. The study is designed to enroll a total of six patients. In addition to evaluating safety, the trial will examine indicators of potential efficacy, including the degree of ascites fluid generation and the need for paracentesis procedures. It will also evaluate the steady-state pharmacokinetics of terlipressin and its active metabolite.